Esperion Therapeutics IncESPR
Price$3.18

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $418.2M+25.9% YoYTTM through 31 Mar 2026
Net Income -$7.4MTTM through 31 Mar 2026
Free Cash Flow -$18.4MTTM through 31 Mar 2026

Margins

Current
Gross Margin68.0%
EBITDA Margin18.1%
Operating Margin1,495.0%
Net Margin-1.8%

Returns

2.4%ROE

Balance Sheet Health

Debt / Equity-0.81x
Current Ratio1.54x
Net Debt$93.9M
Cash & Equivalents$156.2M

Quality Metrics

Altman Z-Score-2.50
Piotroski F-Score2 / 9
FCF Margin-4.4%
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $403.1M
Diluted EPS-$0.00TTM
'19'20'21'22'23'24'25
FY2025: $-0.11

Dividend

No dividend

Capital Allocation

Capex Intensity0.0%

Segment Performance

SegmentRevenueYoYOutlook
U.S. Net Product Revenue$159.6M+38.0%
Collaboration Revenue$243.6M+12.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.